In phase I/II study evaluating the safety and efficacy of relatlimab (anti-LAG-3) in combination with nivolumab in patients with advanced melanoma that had progressed during previous anti-PD-1 or anti-PD-L1 immunotherapy (NCT0198609), the combination of relatlimab and nivolumab was well tolerated and the objective response rate (ORR) was 11.5% in 61 patients. Here, LAG3 is linked to melanoma.